| Primary |
| Asthma |
26.5% |
| Premedication |
11.3% |
| Crohn's Disease |
8.3% |
| Adrenocortical Insufficiency Acute |
5.9% |
| Adrenal Insufficiency |
4.9% |
| Hypersensitivity |
4.4% |
| Prophylaxis |
4.4% |
| Pyrexia |
4.4% |
| Pneumonia |
3.4% |
| Urticaria |
3.4% |
| Chemotherapy |
2.9% |
| Interstitial Lung Disease |
2.9% |
| Sepsis |
2.9% |
| Facial Palsy |
2.5% |
| Addison's Disease |
2.0% |
| Drug Hypersensitivity |
2.0% |
| Drug Use For Unknown Indication |
2.0% |
| Isolated Adrenocorticotropic Hormone Deficiency |
2.0% |
| Myelofibrosis |
2.0% |
| Pulmonary Fibrosis |
2.0% |
|
| Shock |
26.0% |
| Urticaria |
8.3% |
| Anaphylactic Shock |
6.3% |
| Anaphylactic Reaction |
5.2% |
| Asthma |
5.2% |
| Wrong Technique In Drug Usage Process |
5.2% |
| Pruritus |
4.2% |
| Skin Irritation |
4.2% |
| Bronchopulmonary Aspergillosis Allergic |
3.1% |
| Erythema Multiforme |
3.1% |
| Platelet Count Decreased |
3.1% |
| Respiratory Arrest |
3.1% |
| Reversible Posterior Leukoencephalopathy Syndrome |
3.1% |
| Septic Shock |
3.1% |
| Vision Blurred |
3.1% |
| Visual Impairment |
3.1% |
| Wheezing |
3.1% |
| White Blood Cell Count Increased |
3.1% |
| Acute Hepatic Failure |
2.1% |
| Adrenocortical Insufficiency Acute |
2.1% |
|
| Secondary |
| Crohn's Disease |
17.0% |
| Prophylaxis |
14.8% |
| Premedication |
13.4% |
| Juvenile Arthritis |
6.7% |
| Drug Use For Unknown Indication |
5.6% |
| Prophylaxis Against Renal Transplant Rejection |
4.9% |
| Acute Lymphocytic Leukaemia |
4.6% |
| Rheumatoid Arthritis |
3.5% |
| Acute Myeloid Leukaemia |
3.2% |
| Acute Myelomonocytic Leukaemia |
3.2% |
| Asthma |
2.8% |
| Infection Prophylaxis |
2.6% |
| Pain |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.3% |
| Pyrexia |
2.3% |
| Cancer Pain |
2.1% |
| Constipation |
2.1% |
| Interstitial Lung Disease |
2.1% |
| Pneumonia |
2.1% |
| Pneumonia Aspiration |
2.1% |
|
| Reversible Posterior Leukoencephalopathy Syndrome |
13.3% |
| Vomiting |
13.3% |
| Urticaria |
8.4% |
| Herpes Zoster |
6.0% |
| Dyspnoea |
4.8% |
| Shock |
4.8% |
| Tuberculosis |
4.8% |
| Anaphylactic Shock |
3.6% |
| Cerebral Haemorrhage |
3.6% |
| Erythema Multiforme |
3.6% |
| Hepatic Function Abnormal |
3.6% |
| Oxygen Saturation Decreased |
3.6% |
| Pallor |
3.6% |
| Pyrexia |
3.6% |
| Skin Reaction |
3.6% |
| Ureteric Obstruction |
3.6% |
| Weight Decreased |
3.6% |
| White Blood Cell Count Decreased |
3.6% |
| Convulsion |
2.4% |
| Endotoxic Shock |
2.4% |
|
| Concomitant |
| Premedication |
24.1% |
| Product Used For Unknown Indication |
15.8% |
| Drug Use For Unknown Indication |
12.5% |
| Prophylaxis |
11.3% |
| Crohn's Disease |
8.4% |
| Multiple Myeloma |
3.2% |
| Hypertension |
3.1% |
| Rheumatoid Arthritis |
2.9% |
| Stem Cell Transplant |
2.1% |
| Pain |
2.0% |
| Colitis Ulcerative |
2.0% |
| Infection Prophylaxis |
1.8% |
| Constipation |
1.7% |
| Acute Myeloid Leukaemia |
1.5% |
| Nausea |
1.5% |
| Sedation |
1.5% |
| Insomnia |
1.3% |
| Myelodysplastic Syndrome |
1.1% |
| Gout |
1.1% |
| Analgesic Therapy |
1.0% |
|
| Vomiting |
12.1% |
| Pneumonia |
9.5% |
| Infusion Related Reaction |
9.1% |
| Sepsis |
8.8% |
| White Blood Cell Count Decreased |
7.4% |
| Pyrexia |
6.7% |
| Urticaria |
6.7% |
| Death |
4.2% |
| Rash |
4.2% |
| Renal Failure |
3.8% |
| Nausea |
3.5% |
| Thrombocytopenia |
3.3% |
| Dyspnoea |
3.2% |
| Weight Increased |
3.0% |
| Platelet Count Decreased |
2.6% |
| Shock |
2.6% |
| White Blood Cell Count Increased |
2.6% |
| Renal Impairment |
2.3% |
| Urinary Tract Infection |
2.3% |
| Crohn's Disease |
2.1% |
|
| Interacting |
|
|
